公开(公告)号：US20160279246A1

公开(公告)日：2016-09-29

申请号：US15054956

申请日：2016-02-26

Applicant: Massachusetts Institute of Technology

Inventor： Bernhardt Levy Trout ,  Allan Stuart Myerson ,  Siva Rama Krishna Perala ,  Christopher James Testa ,  Keith Dale Jensen

IPC: A61K47/26 ,  A61K31/167

CPC classification number: A61K47/26 ,  A61K31/167 ,  B01D9/0036 ,  B01D9/0059

Abstract: Methods of heterogeneous crystallization and related systems are provided. In some embodiments, a method comprises crystallizing an agent in a suspension comprising a heteronucleant and the dissolved agent. Crystallization may occur on the surface of the heteronucleant with little or no bulk crystallization and/or secondary nucleation. In some embodiments, a crystallizer may be configured to inhibit secondary nucleation and/or bulk crystallization, for example, by reducing the formation of free crystals that may serve as nucleation surfaces while allowing for adequate mass and heat transfer. In some such embodiments, the crystallizer may be designed to flow (e.g., continuously) a suspension comprising a heteronucleant and an agent in a fluidized state. The methods and systems of the present invention may be used in a wide variety of applications, including the crystallization of pharmaceutically active agents.

Abstract translation: 提供了异相结晶和相关系统的方法。 在一些实施方案中，一种方法包括使包含异源核苷酸和溶解试剂的悬浮液中的试剂结晶。 结晶可能发生在异源核的表面上，很少或没有本体结晶和/或二次成核。 在一些实施方案中，结晶器可以被配置为抑制二次成核和/或体积结晶，例如通过减少可用作成核表面的自由晶体的形成，同时允许足够的质量和热传递。 在一些这样的实施方案中，结晶器可以被设计成流动（例如，连续地）流态化的包含异源核苷酸和试剂的悬浮液。 本发明的方法和系统可以用于各种应用，包括药物活性剂的结晶。